Journal
VACCINES
Volume 9, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/vaccines9040395
Keywords
COVID-19; vaccine; virus-like particle; CuMVTT-RBD; BLI
Categories
Funding
- Saiba AG
- Swiss National Science Foundation (SNF) [31003A_185114]
- International Immunology Centre, Anhui Agricultural University, Hefei, China
Ask authors/readers for more resources
The COVID-19 pandemic, caused by a new coronavirus, has led to a significant global health crisis with over 110 million cases and 2 million deaths recorded. Rapid development of a protective vaccine is crucial in combating the virus.
The ongoing coronavirus disease (COVID-19) pandemic is caused by a new coronavirus (severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)) first reported in Wuhan City, China. From there, it has been rapidly spreading to many cities inside and outside China. Nowadays, more than 110 million cases with deaths surpassing 2 million have been recorded worldwide, thus representing a major health and economic issues. Rapid development of a protective vaccine against COVID-19 is therefore of paramount importance. Here, we demonstrated that the recombinantly expressed receptor-binding domain (RBD) of the spike protein can be coupled to immunologically optimized virus-like particles derived from cucumber mosaic virus (CuMVTT). The RBD displayed CuMVTT bound to ACE2, the viral receptor, demonstrating proper folding of RBD. Furthermore, a highly repetitive display of the RBD on CuMVTT resulted in a vaccine candidate that induced high levels of specific antibodies in mice, which were able to block binding of the spike protein to ACE2 and potently neutralize SARS-CoV-2 virus in vitro.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available